Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic
outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between
CES1 genotypes and the PK and PD of MPH.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Children's Hospital Medical Center, Cincinnati Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Seattle Children's Hospital University of Florida